MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1378/chest.10-2948

Медицинская библиотека · Chest · 2011

The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study.

Kim Victor, Han MeiLan K, Vance Gwendolyn B, Make Barry J, Newell John D, Hokanson John E, Hersh Craig P, Stinson Douglas, Silverman Edwin K, Criner Gerard J, COPDGene Investigators

СтатьяПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

BACKGROUND

Chronic bronchitis (CB) in patients with COPD is associated with an accelerated lung function decline and an increased risk of respiratory infections. Despite its clinical significance, the chronic bronchitic phenotype in COPD remains poorly defined.

METHODS

We analyzed data from subjects enrolled in the Genetic Epidemiology of COPD (COPDGene) Study. A total of 1,061 subjects with GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage II to IV were divided into two groups: CB (CB+) if subjects noted chronic cough and phlegm production for ≥ 3 mo/y for 2 consecutive years, and no CB (CB-) if they did not.

RESULTS

There were 290 and 771 subjects in the CB+ and CB- groups, respectively. Despite similar lung function, the CB+ group was younger (62.8 ± 8.4 vs 64.6 ± 8.4 years, P = .002), smoked more (57 ± 30 vs 52 ± 25 pack-years, P = .006), and had more current smokers (48% vs 27%, P < .0001). A greater percentage of the CB+ group reported nasal and ocular symptoms, wheezing, and nocturnal awakenings secondary to cough and dyspnea. History of exacerbations was higher in the CB+ group (1.21 ± 1.62 vs 0.63 ± 1.12 per patient, P < .027), and more patients in the CB+ group reported a history of severe exacerbations (26.6% vs 20.0%, P = .024). There was no difference in percent emphysema or percent gas trapping, but the CB+ group had a higher mean percent segmental airway wall area (63.2% ± 2.9% vs 62.6% ± 3.1%, P = .013).

CONCLUSIONS

CB in patients with COPD is associated with worse respiratory symptoms and higher risk of exacerbations. This group may need more directed therapy targeting chronic mucus production and smoking cessation not only to improve symptoms but also to reduce risk, improve quality of life, and improve outcomes.

TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00608764; URL: www.clinicaltrials.gov.

Для цитирования: Kim Victor, Han MeiLan K, Vance Gwendolyn B, Make Barry J, Newell John D, Hokanson John E, Hersh Craig P, Stinson Douglas, Silverman Edwin K, Criner Gerard J, COPDGene Investigators. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study.. Chest. 2011. DOI: 10.1378/chest.10-2948.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.